90 related articles for article (PubMed ID: 24676892)
1. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
2. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
3. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
5. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
[No Abstract] [Full Text] [Related]
8. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
Lamont EB; Schilsky RL; He Y; Muss H; Cohen HJ; Hurria A; Meilleur A; Kindler HL; Venook A; Lilenbaum R; Niell H; Goldberg RM; Joffe S;
J Natl Cancer Inst; 2015 Jan; 107(1):336. PubMed ID: 25432408
[TBL] [Abstract][Full Text] [Related]
9. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.
Brizzi MP; Berruti A; Ferrero A; Milanesi E; Volante M; Castiglione F; Birocco N; Bombaci S; Perroni D; Ferretti B; Alabiso O; Ciuffreda L; Bertetto O; Papotti M; Dogliotti L
BMC Cancer; 2009 Nov; 9():388. PubMed ID: 19886987
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
[TBL] [Abstract][Full Text] [Related]
11. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Koumarianou A; Antoniou S; Kanakis G; Economopoulos N; Rontogianni D; Ntavatzikos A; Tsavaris N; Pectasides D; Dimitriadis G; Kaltsas G
Endocr Relat Cancer; 2012 Feb; 19(1):L1-4. PubMed ID: 22232542
[No Abstract] [Full Text] [Related]
13. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
Ammann M; Kinney MAO; Gudmundsdottir H; Santol J; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Anderson AL; Halfdanarson TR; Nagorney DM; Starlinger PP
Ann Surg Oncol; 2024 Jun; 31(6):3976-3977. PubMed ID: 38619707
[No Abstract] [Full Text] [Related]
14. Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States.
Nadpara PA; Madhavan SS; Tworek C; Sambamoorthi U; Hendryx M; Almubarak M
J Geriatr Oncol; 2015 Mar; 6(2):101-10. PubMed ID: 25604094
[TBL] [Abstract][Full Text] [Related]
15. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis.
Beg MS; Gupta A; Sher D; Ali S; Khan S; Gao A; Stewart T; Ahn C; Berry J; Mortensen EM
Am J Clin Oncol; 2018 Aug; 41(8):766-771. PubMed ID: 28079594
[TBL] [Abstract][Full Text] [Related]
16. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Kulke MH; Siu LL; Tepper JE; Fisher G; Jaffe D; Haller DG; Ellis LM; Benedetti JK; Bergsland EK; Hobday TJ; Van Cutsem E; Pingpank J; Oberg K; Cohen SJ; Posner MC; Yao JC
J Clin Oncol; 2011 Mar; 29(7):934-43. PubMed ID: 21263089
[TBL] [Abstract][Full Text] [Related]
17. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study.
von Arx C; Rea G; Napolitano M; Ottaiano A; Tatangelo F; Izzo F; Petrillo A; Clemente O; Di Sarno A; Botti G; Scala S; Tafuto S
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32859050
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.
Di Giacinto P; Rota F; Rizza L; Campana D; Isidori A; Lania A; Lenzi A; Zuppi P; Baldelli R
Int J Endocrinol; 2018; 2018():8126087. PubMed ID: 30057604
[No Abstract] [Full Text] [Related]
19. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
Mulvey CK; Paciorek A; Moon F; Steiding P; Shih B; Gubens MA; Zhang L; Bergsland EK; Cheng I
Endocr Relat Cancer; 2024 Jan; 31(1):. PubMed ID: 37882324
[TBL] [Abstract][Full Text] [Related]
20. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.
Cioppi F; Cianferotti L; Masi L; Giusti F; Brandi ML
Clin Cases Miner Bone Metab; 2017; 14(2):123-130. PubMed ID: 29263719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
